Caryn Crame

Caryn joined Vericel in 2011 and is responsible for Clinical Development, Clinical Operations, and Clinical Programming and Data Management, in addition to overseeing all scientific communications and responses to FDA product-related clinical queries. Prior to joining Vericel, Caryn served as Director, Transplant & Oncology Scientific Reporting at Genzyme where she worked primarily on Phase 3 orphan drug submissions, Agency responses, and managed a medical writing group. During her nine-year tenure at Pfizer, she was a Director within the Regulatory Submissions group and managed colleagues as well as contributed authorship to NDAs, MAAs, Agency responses and worked on multiple drug development teams. Throughout her career, Caryn has worked on numerous projects in the field of Epidemiology including a study on dementia and statins with the University of Michigan, registry studies, an Agency response for the analysis of the association of antidepressants with suicidality in pediatric patients, and multiple Orphan Drug applications. Caryn holds a PhD in Epidemiology and a M.S. in Environmental Studies/Toxicology from the University of Michigan.